Potential biosimilars savings in EU5 countries and the U.S. 2016-2020

This statistic shows the potential cumulative savings due to the introduction of biosimilars for 8 key products combined in EU-5 countries and the U.S. between 2016 and 2020. Until 2017, assuming a price reduction of 20 percent for the 8 key products' biosimilars, savings would reach around 9 billion U.S. dollars.

Potential savings due to biosimilars for 8 key products combined in EU-5 countries and the U.S. between 2016 and 2020 (in billion euros)*

20% price reduction30% price reduction40% price reduction
----
----
----
----
----
Exclusive Premium statistic

You need a Premium Account for unlimited access.

  • Full access to 1m statistics

  • Incl. source references

  • Available to download in PNG, PDF, XLS format

Premium Account

only $59 / month *
*Duration: 12 months, billed annually, single license

Access to this and all other statistics on 80,000 topics from

$708 / Year

Show detailed source information?
Register for free
Already a member?
Log in
Sources

Release date

September 2016

Region

United States, EU

Survey time period

as of December 2015

Supplementary notes

* Savings potential in EU5+US biosimilar accessible market dependent on change in price per treatment day. The accessible market analysis is based on Adalimumab, Insulin glargine, Etanercept, Infliximiab, Rituximab, Peg-filgrastim, Trastuzumab and Follitropin alpha. Savings potential in biosimilar accessible market at different price levels is calculated based on extrapolated size of the originator market between 2016 and 2020 based on historic CAGR and analogues. Accumulation of savings potential between 2016-2020 is shown.
EU-5 includes Germany, UK, France, Italy, and Spain.

Statista Accounts: Access All Statistics. Starting from $708 / Year
Basic Account
Get to know the platform

You only have access to basic statistics.
This statistic is not included in your account!

Premium Account
Your perfect start with Statista
  • Instant access to 1m statistics
  • Download in XLS, PDF & PNG format
  • Detailed references

$59 / Month *

Corporate Account
Full access

Corporate solution including all features.

* All products require an annual contract.
   Prices do not include sales tax.

Statistics on "Pharmaceutical industry in Norway "

Statista Accounts: Access All Statistics. Starting from $708 / Year
Learn more about how Statista can support your business.